KWM
ABBV icon

Keebeck Wealth Management’s AbbVie ABBV Stock Holding History

Keebeck Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54M Buy
22,005
+1,401
+7% +$301K 0.54% 44
2026
Q1 		$4.48M Sell
20,604
-3,324
-14% -$737K 0.5% 49
2025
Q4 		$5.47M Sell
23,928
-623
-3% -$142K 0.63% 34
2025
Q3 		$5.68M Sell
24,551
-57
-0.2% -$11.6K 0.67% 38
2025
Q2 		$4.57M Sell
24,608
-548
-2% -$102K 0.6% 46
2025
Q1 		$5.27M Buy
25,156
+148
+0.6% +$28.8K 0.78% 34
2024
Q4 		$4.44M Sell
25,008
-141
-0.6% -$25.9K 0.64% 44
2024
Q3 		$4.97M Sell
25,149
-234
-0.9% -$43.7K 0.72% 40
2024
Q2 		$4.35M Buy
25,383
+8,711
+52% +$1.44M 0.64% 41
2024
Q1 		$3.04M Buy
16,672
+13,380
+406% +$2.31M 0.45% 63
2023
Q4 		$510K Buy
3,292
+77
+2% +$11.2K 0.08% 174
2023
Q3 		$479K Buy
3,215
+168
+6% +$24.7K 0.08% 177
2023
Q2 		$411K Buy
3,047
+35
+1% +$5.13K 0.06% 193
2023
Q1 		$480K Sell
3,012
-716
-19% -$109K 0.08% 165
2022
Q4 		$602K Buy
3,728
+22
+0.6% +$3.37K 0.11% 140
2022
Q3 		$497K Buy
3,706
+8
+0.2% +$1.15K 0.1% 150
2022
Q2 		$566K Buy
3,698
+7
+0.2% +$1.07K 0.11% 146
2022
Q1 		$598K Buy
3,691
+8
+0.2% +$1.16K 0.1% 150
2021
Q4 		$499K Buy
3,683
+312
+9% +$36.9K 0.09% 149
2021
Q3 		$364K Buy
3,371
+8
+0.2% +$914 0.07% 160
2021
Q2 		$379K Sell
3,363
-16,896
-83% -$1.9M 0.05% 188
2021
Q1 		$2.19M Sell
20,259
-114
-0.6% -$12.2K 0.34% 59
2020
Q4 		$2.18M Buy
20,373
+11
+0.1% +$1.06K 0.38% 55
2020
Q3 		$1.78M Buy
20,362
+904
+5% +$85.1K 0.37% 54
2020
Q2 		$1.91M Buy
+19,458
New +$1.71M 0.6% 38
2020
Q1 		– Sell
-2,458
Closed -$217K – 140
2019
Q4 		$217K Buy
+2,458
New +$204K 0.07% 136

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Keebeck Wealth Management's ABBV Position: Q2 2026 in Review

Keebeck Wealth Management increased its AbbVie (ABBV) stake by 6.8% in Q2 2026, buying an estimated $301K and bringing the position to 22,005 shares worth $5.54M. The position accounts for 0.54% of the portfolio, ranked #44.

Keebeck Wealth Management first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.68M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Keebeck Wealth Management held 22,005 shares of AbbVie worth $5.54M as of Q2 2026.
  • Keebeck Wealth Management bought 1,401 AbbVie shares in Q2 2026, an estimated $301K.
  • AbbVie made up 0.54% of Keebeck Wealth Management's portfolio in Q2 2026, its #44 holding.
  • Keebeck Wealth Management first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Keebeck Wealth Management's AbbVie position peaked at $5.68M in Q3 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Keebeck Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.